Immuneering Corporation

“We’ve seen some tremendous acceleration in science over the past few years and that science is the driving force behind new medicines. The fundamental need for these new medicines is the underpinning

Biotechnology stocks in the US are still trading lower year-to-date, but valuations have risen significantly in April, suggesting that perhaps the winter chill hovering over the industry is beginning

With investors closely watching how biopharmaceutical companies are spending the cash they have on hand so that they do not run out of money in a tough fundraising environment, even firms with revenue

Ten biopharmaceutical companies launched initial public offerings in the US during the last week of July, raising $1.2bn combined, bringing last month’s total to 18 IPOs. Added to the 62 first-time of